Mucin-degrading microflora for prophylactic antibiotics

Information

  • Research Project
  • 7220223
  • ApplicationId
    7220223
  • Core Project Number
    R43AI063791
  • Full Project Number
    1R43AI063791-01A2
  • Serial Number
    63791
  • FOA Number
    PA-06-34
  • Sub Project Id
  • Project Start Date
    5/15/2007 - 18 years ago
  • Project End Date
    4/30/2009 - 16 years ago
  • Program Officer Name
    VAN DE VERG, LILLIAN L.
  • Budget Start Date
    5/15/2007 - 18 years ago
  • Budget End Date
    4/30/2008 - 17 years ago
  • Fiscal Year
    2007
  • Support Year
    1
  • Suffix
    A2
  • Award Notice Date
    5/4/2007 - 18 years ago
Organizations

Mucin-degrading microflora for prophylactic antibiotics

[unreadable] DESCRIPTION (provided by applicant): This resubmitted Phase I SBIR application focuses on the development of a mucin-degrading colonic flora that competitively excludes Clostridium difficile, a gram-positive anaerobe that causes antibiotic-associated intestinal disease ranging from mild diarrhea to life-theatening pseudomembranous colitis. We are targeting C. difficile because this pathogen already is a major healthcare problem in the U.S., with over 300,000 cases per year and a relapse rate approaching 20%. In the event of massive antimicrobial prophylaxis, there will be a much larger population highly susceptible to infection with C. difficile. C. difficile also could be genetically manipulated to express other toxins such as the select agents, epsilon and botulinum toxins. Previous studies have shown that members of the Clostridium coccoides group degrade and utilize mucin, and competitively exclude C. difficile from the intestine. In Aim 1, we will identify and characterize potential members of a mucin-degrading flora from the coccoides group. We will identify the coccoides group members that most effectively metabolize mucins. The growth and maintenance procedures for the top mucin-degrading strains will be established. In Aim 2, we will determine the in vitro and in vivo performance characteristics of a mucin-degrading flora. The flora will be evaluated for protection and treatment efficacy in the hamster model of antibiotic-associated diarrhea and colitis. Members of an effective flora will be screened for the absence of transferable antibiotic resistance genes and toxin genes. In Phase 2, our studies will be extended to produce the mucin-degrading flora under GMP and initiate clinical studies with the flora under the direction of Dr. Kenneth Wilson at Duke University. Our goal is to determine if the mucin-degrading flora restores or preserves normal mucin metabolism, enhances resistance to colonization by C. difficile, and reduces the incidence of C. difficile- induced antibiotic-associated diarrhea. [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    274969
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
    NIAID:274969\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    TECHLAB, INC.
  • Organization Department
  • Organization DUNS
    614218634
  • Organization City
    BLACKSBURG
  • Organization State
    VA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    24060
  • Organization District
    UNITED STATES